<DOC>
	<DOCNO>NCT00428766</DOCNO>
	<brief_summary>The purpose study establish safe dose MORAb-003 subject advanced ovarian cancer . MORAb-003 antibody direct antigen surface ovarian cancer cell .</brief_summary>
	<brief_title>Safety , Tolerability Pharmacokinetics MORAb-003 Subjects With Advanced Ovarian Cancer</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Glandular Epithelial</mesh_term>
	<criteria>1 . Female subject , ≥18 year age , histologically confirm epithelial ovarian , fallopian tube , primary peritoneal adenocarcinoma , without elevation CA 125 , confirm Department Pathology , Memorial SloanKettering Cancer Center . 2 . Subject must disease , define Response Evaluation Criteria Solid Tumors ( RECIST ) evaluable clinical signs/symptoms ( e.g. , ascites , pleural effusion , lesion less 2 cm ) support CA125 , radiologic , pathologic study conduct within 4 week prior study entry . 3 . Subject must fail least standard ( platinumcontaining ) chemotherapy regimen consider platinum refractory resistant . 4 . Life expectancy ≥3 month , estimate investigator . 5 . Karnofsky performance status ≥70 % . 6 . Subjects must surgically sterile , postmenopausal , use effective form contraception . 7 . Subjects undergoing treatment medication must stable medication regimen least 30 day prior Study Day 1 . 8 . Laboratory clinical result within 2 week prior Study Day 1 follow : Absolute neutrophil count ( ANC ) ≥1.5 x 109/L Platelet count ≥100 x 109/L Hemoglobin ≥10 g/dL Serum bilirubin ≤2.0 mg/dL Aspartate transaminase ( AST ) ≤2.5 x upper limit normal ( ULN ) Alanine transaminase ( ALT ) ≤2.5 x ULN Serum creatinine ≤2.0 mg/dL Amylase ≤1.5 x ULN Lipase ≤1.5 x ULN 9 . Spirometry indicate FEV1 &gt; 79 % predict . 10 . Subject must willing able provide write informed consent . 1 . Known central nervous system ( CNS ) tumor involvement . 2 . Evidence active malignancy . 3 . Active asthma chronic lung disease . 4 . Clinically significant heart disease ( e.g. , congestive heart failure New York Heart Association Class III IV , angina well controlled medication , myocardial infarction within 6 month ) . 5 . ECG demonstrate clinically significant arrhythmia ( Note : Subjects chronic atrial arrhythmia , i.e. , atrial fibrillation paroxysmal SVT , eligible ) . 6 . Active serious systemic disease , include active bacterial fungal infection . 7 . Chronic inflammatory bowel disease . 8 . Chemotherapy , biologic therapy , immunotherapy within 3 week prior enrollment . 9 . Breastfeeding , pregnant , likely become pregnant study . 10 . Active hepatitis HIV infection . 11 . Subjects receive previous monoclonal antibody therapy evidence immune allergic reaction , document HAHA . 12 . Subjects large ascites ( ≥500 cc base result recent CT scan ) .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
</DOC>